Vanda Pharmaceuticals Inc.
DE ˙ DB ˙ US9216591084
5,26 € ↑0,09 (1,74%)
2026-06-05
DEL PRIS
SecurityDE:VM4 / Vanda Pharmaceuticals Inc.
InstitutionJpmorgan Chase & Co
Latest Disclosed Ownership304,894 shares
Latest Disclosed Value $ 2,027,546
Jpmorgan Chase & Co ownership in VM4 / Vanda Pharmaceuticals Inc.

On May 13, 2026 - Jpmorgan Chase & Co filed a 13F-HR/A form disclosing ownership of 304,894 shares of Vanda Pharmaceuticals Inc. (DE:VM4) valued at $1,753,140 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 396,017 shares of Vanda Pharmaceuticals Inc.. This represents a change in shares of -23.01% during the quarter. The current value of the position is $1,603,742 USD.

Jpmorgan Chase & Co has a history of taking positions in derivatives of the underlying security (VM4) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:VM4 / Vanda Pharmaceuticals Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F/A-1 VANDA PHARMACEUTICALS COMMON 921659108 304,894 -91,123 -23.01 2,028 -41.95 0.0000
2026-02-11 2025-12-31 13F VANDA PHARMACEUTICALS COMMON 921659108 396,017 196,124 98.11 3,493 250.25 0.0002
2025-11-26 2025-09-30 13F/A-1 VANDA PHARMACEUTICALS COMMON 921659108 199,893 28,238 16.45 997 23.09 0.0001
2025-11-07 2025-09-30 13F VANDA PHARMACEUTICALS COMMON 921659108 199,893 28,238 997 0.0000
2025-08-12 2025-06-30 13F VANDA PHARMACEUTICALS COMMON 921659108 171,655 -178,946 -51.04 810 -49.66 0.0001
2025-05-12 2025-03-31 13F VANDA PHARMACEUTICALS COMMON 921659108 350,601 14,860 4.43 1,609 0.06 0.0001
2025-02-12 2024-12-31 13F VANDA PHARMACEUTICALS COMMON 921659108 335,741 175,019 108.90 1,608 113.55 0.0001
2024-12-26 2024-09-30 13F/A-1 VANDA PHARMACEUTICALS COMMON 921659108 160,722 22,249 16.07 754 -3.71 0.0001
2024-11-08 2024-09-30 13F VANDA PHARMACEUTICALS COMMON 921659108 160,722 22,249 754 0.0001
2024-12-26 2024-06-30 13F/A-1 VANDA PHARMACEUTICALS COMMON 921659108 138,473 -142,310 -50.68 782 -32.24 0.0001
2024-08-12 2024-06-30 13F VANDA PHARMACEUTICALS COMMON 921659108 138,473 -142,310 782 0.0001
2024-12-26 2024-03-31 13F/A-1 VANDA PHARMACEUTICALS COMMON 921659108 280,783 74,752 36.28 1,154 32.80 0.0001
2024-05-10 2024-03-31 13F VANDA PHARMACEUTICALS COMMON 921659108 280,783 74,752 1,154 0.0001
2024-12-26 2023-12-31 13F/A-1 VANDA PHARMACEUTICALS COMMON 921659108 206,031 -21,234 -9.34 869 -11.42 0.0001
2024-02-12 2023-12-31 13F VANDA PHARMACEUTICALS COMMON 921659108 206,031 -21,234 869 0.0001
2023-11-14 2023-09-30 13F VANDA PHARMACEUTICALS COMMON 921659108 227,265 95,615 72.63 982 13.15 0.0001
2023-08-11 2023-06-30 13F VANDA PHARMACEUTICALS COMMON 921659108 131,650 -76,222 -36.67 868 -38.55 0.0001
2023-05-18 2023-03-31 13F/A-1 VANDA PHARMACEUTICALS COMMON 921659108 207,872 -13,412 -6.06 1,411 141,000.00 0.0002
2023-05-11 2023-03-31 13F VANDA PHARMACEUTICALS COMMON 921659108 165,347 -55,937 1,122 0.0000
2023-02-13 2022-12-31 13F VANDA PHARMACEUTICALS COMMON 921659108 221,284 74,323 50.57 2 -99.93 0.0002
2022-11-14 2022-09-30 13F VANDA PHARMACEUTICALS COMMON 921659108 146,961 41,849 39.81 1,452 26.81 0.0002
2022-08-11 2022-06-30 13F VANDA PHARMACEUTICALS COMMON 921659108 105,112 -258,656 -71.10 1,145 -72.17 0.0002
2022-05-11 2022-03-31 13F VANDA PHARMACEUTICALS COMMON 921659108 363,768 16,716 4.82 4,114 -24.43 0.0005
2022-02-11 2021-12-31 13F/A-1 VANDA PHARMACEUTICALS COMMON 921659108 347,052 -2,938 -0.84 5,444 -9.25 0.0006
2022-02-10 2021-12-31 13F VANDA PHARMACEUTICALS COMMON 921659108 347,052 -2,938 5,444 0.0001
2021-11-12 2021-09-30 13F VANDA PHARMACEUTICALS COMMON 921659108 349,990 -23,841 -6.38 5,999 -25.40 0.0007
2021-08-12 2021-06-30 13F VANDA PHARMACEUTICALS COMMON 921659108 373,831 74,483 24.88 8,042 78.87 0.0010
2021-05-12 2021-03-31 13F VANDA PHARMACEUTICALS COMMON 921659108 299,348 -66,689 -18.22 4,496 -6.55 0.0006
2021-02-19 2020-12-31 13F/A-1 VANDA PHARMACEUTICALS COMMON 921659108 366,037 225,435 160.34 4,811 260.10 0.0007
2021-02-11 2020-12-31 13F VANDA PHARMACEUTICALS COMMON 921659108 366,037 225,435 4,811 118.9795
2020-11-12 2020-09-30 13F/A-1 VANDA PHARMACEUTICALS COMMON 921659108 140,602 -10,744 -7.10 1,336 -22.82 0.0002
2020-11-12 2020-09-30 13F VANDA PHARMACEUTICALS COMMON 921659108 140,602 1,336
2020-08-11 2020-06-30 13F VANDA PHARMACEUTICALS COMMON 921659108 151,346 -20,846 -12.11 1,731 -2.97 0.0003
2020-05-12 2020-03-31 13F VANDA PHARMACEUTICALS COMMON 921659108 172,192 -17,156 -9.06 1,784 -42.58 0.0004
2020-02-11 2019-12-31 13F VANDA PHARMACEUTICALS COMMON 921659108 189,348 -13,977 -6.87 3,107 15.07 0.0006
2019-11-12 2019-09-30 13F VANDA PHARMACEUTICALS COMMON 921659108 203,325 -97,602 -32.43 2,700 -37.77 0.0005
2019-08-07 2019-06-30 13F VANDA PHARMACEUTICALS COMMON 921659108 300,927 99,602 49.47 4,339 17.11 0.0008
2019-05-07 2019-03-31 13F VANDA PHARMACEUTICALS COMMON 921659108 201,325 -32,403 -13.86 3,705 -39.34 0.0008
2019-02-11 2018-12-31 13F VANDA PHARMACEUTICALS COMMON 921659108 233,728 -57,367 -19.71 6,108 -8.58 0.0014
2018-11-13 2018-09-30 13F/A-1 VANDA PHARMACEUTICALS COMMON 921659108 291,095 -19,675 -6.33 6,681 12.85 0.0013
2018-11-07 2018-09-30 13F VANDA PHARMACEUTICALS COMMON 921659108 291,095 -19,675 6,681
2018-08-14 2018-06-30 13F VANDA PHARMACEUTICALS COMMON 921659108 310,770 21,301 7.36 5,920 21.39 0.0012
2018-05-10 2018-03-31 13F VANDA PHARMACEUTICALS COMMON 921659108 289,469 -90,360 -23.79 4,877 -15.52 0.0010
2018-02-13 2017-12-31 13F VANDA PHARMACEUTICALS COMMON 921659108 379,829 320,491 540.11 5,773 439.03 0.0012
2017-11-09 2017-09-30 13F VANDA PHARMACEUTICALS COMMON 921659108 59,338 -80,835 -57.67 1,071 -53.13 0.0002
2017-08-09 2017-06-30 13F VANDA PHARMACEUTICALS COMMON 921659108 140,173 -1,878 -1.32 2,285 14.88 0.0005
2017-05-10 2017-03-31 13F VANDA PHARMACEUTICALS COMMON 921659108 142,051 -38,261 -21.22 1,989 -30.84 0.0005
2017-02-06 2016-12-31 13F VANDA PHARMACEUTICALS COMMON 921659108 180,312 25,999 16.85 2,876 11.99 0.0007
2016-11-04 2016-09-30 13F VANDA PHARMACEUTICALS COMMON 921659108 154,313 84,401 120.72 2,568 228.39 0.0006
2016-08-08 2016-06-30 13F VANDA PHARMACEUTICALS COMMON 921659108 69,912 69,654 26,997.67 782 39,000.00 0.0002
2016-05-10 2016-03-31 13F VANDA PHARMACEUTICALS COMMON 921659108 258 0 0.00 2 0.00 0.0000
2016-02-12 2015-12-31 13F VANDA PHARMACEUTICALS COMMON 921659108 258 258 2 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2019-05-07 2019-03-31 13F VANDA PHARMACEUTICALS OPTION Call 0 -100.00 0 -100.00 n/a n/a n/a
2019-02-11 2018-12-31 13F VANDA PHARMACEUTICALS OPTION Call 85,400 2,232 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2019-05-07 2019-03-31 13F VANDA PHARMACEUTICALS OPTION Put 0 -100.00 0 -100.00 n/a n/a n/a
2019-02-11 2018-12-31 13F VANDA PHARMACEUTICALS OPTION Put 73,400 1,918 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.